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Micafungin is fungicidal against Candida strains. In children the
recommended dosage is 2–4 mg/kg (maximum of 100 mg),
once a day for a total of 14–21 days after the last positive
blood culture, but longer administrations might be needed in
the case of deep organ localization [1,2].
A 16-year-old male with acute lymphoblastic leukemia
developed candidaemia with associated hepatic lesions during
neutropenia following the ﬁrst cycle of chemotherapy. The
Broviac catheter was promptly removed and liposomal
amphotericin B was started, but it had to be withdrawn after
the ﬁrst infusion because of severe bronchospasm, and
substituted with micafungin, which had a minimal inhibitory
concentration (MIC) of 0.015 mg/mL (Sensititre YeastOne;
Trek Diagnostic Systems Inc., Cleveland, OH, USA) at 100 mg
once a day. After 2 months of in-hospital stay the patient was
in fair clinical condition but asked for a period of home care.
Clinical conditions were improved as well as hepatic lesions,
which were still present even if with a reduced diameter.
Antifungal treatment should be continued, but a shift to
triazoles was excluded because of a high risk of poor
compliance with oral therapy due to the poor socio-econom-
ical condition of the family; high-dose weekly liposomal
amphotericin B [3] was also excluded because of the severe
adverse event developed at the time of ﬁrst infusion of this
drug. Therefore, we continued micafungin at 100 mg once a
day for 5 days a week (5d/w) administered by the home care
service. This choice was supported by a study showing efﬁcacy
of micafungin prophylaxis administered every other day [4] and
by inference from a case report on 5d/w caspofungin [5].
Micafungin was administered for a total of 6 months, four of
them with the 5d/w schedule, and was effective, with complete
regression of liver lesions, and safe, with absence of any
FIG. 1. Micafungin trough blood concentration and ratio concentration/MIC for C. albicans after 48 h of treatment interruption during 5 days/week
administration.
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abnormality of liver function test or other adverse events
related to this treatment.
During the 5d/w therapy, samples for the determination of
micafungin blood concentrations were taken on the last day of
treatment (Friday) and the ﬁrst day of restarting treatment
(Monday), before (trough) micafungin infusion. Plasma mica-
fungin concentrations were determined by liquid chromatog-
raphy coupled to tandem mass spectrometry as recently
described [6]. Fig. 1 reports micafungin trough concentrations
on four couples Friday–Monday and the ratio between the
blood concentration detected and the MIC of the isolated
Candida albicans strain. Even after 48 h of interruption, trough
blood levels were still more than 10 times higher than the MIC.
Long-term administration of antifungal drugs is needed in
the presence of invasive fungal disease in patients who need
prolonged immunosuppression such as anti-leukaemic chemo-
therapy. Oral triazoles might represent the drug of choice, but
they may result in restriction of the spectrum of activity
(ﬂuconazole), a particular need for administration and/or
important drug interactions (voriconazole, itraconazole and
posaconazole) [7], or a peculiar toxicity associated with
administration of anti-leukaemic drugs [8] or sunlight exposure
(not easily avoidable, especially in Mediterranean regions) [9],
which may preclude their administration. Intermittent admin-
istration of liposomal amphotericin B, caspofungin or micafun-
gin has been proposed for prophylaxis or therapy for invasive
fungal disease in cancer patients [3–5,10–12]. In general, this
practice has been demonstrated to be effective and safe, even
if some toxicity has been observed with the highest doses of
liposomal amphotericin B [3,10,12].
Even if it needs further conﬁrmation, the present experi-
ence suggests that micafungin administered 5 days/week can
be a possible approach for the treatment of patients with
invasive candidiasis who cannot receive other antifungals and
may not be hospitalized for long periods.
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